Fukuoka Prefecture and a Kurume-based startup agreed to co-develop a medication for the treatment of the new coronavirus. Bonac Corporation, a biotechnology company specialized in nucleic acids, aims to bring a new inhalable drug onto the market within the next three years. Direct delivery of the drug to the patient’s lungs could reduce the risk of side effects compared to injections of remdesivir and anti-flu drug Avigan. On May 18, no new case of COVID-19 infection was found in the prefecture. The cumulative total of the virus infection remains at 658. Also, 550 patients in the prefecture have recovered from the disease as of May 17. Sources: TNC / Fukuoka Prefecture / NHK
Disclaimer: Fukuoka Now posts summaries of Kyushu area news for those who cannot read Japanese. Contents posted here are mostly summaries of publicly posted news from the Japanese media. Errors might occur during translation. Those are ours, and not the source’s. Photos and images are sourced separately and are for illustrative purposes only. Please use this form to send feedback and if you enjoy our contents, please share it, that helps.